GlassScriptPhysician profile
Carol Ramirez Rojas
NPI 1063773430
$5,529.76
in general payments reported to CMS, 2019-2025
39 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $716 · 2021: $1,133 · 2022: $351 · 2023: $377 · 2024: $751 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.31 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Amgen INC. | $653.24 | 2019-2025 | Tepezza, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $569.78 | 2020-2025 | |
| Lilly USA, LLC | $299.83 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $264.34 | 2019-2025 | Tymlos |
| Beta Bionics, INC. | $258.66 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $210.88 | 2021-2025 | |
| Amarin Pharma, INC. | $200.42 | 2020-2021 | |
| Cequr Corporation | $192.02 | 2021-2025 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $190.60 | 2020-2022 | |
| Abbott Laboratories | $183.99 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Medtronic, INC. | $154.38 | 2022-2023 | Minimed 780g |
| Abbvie INC. | $149.30 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $131.78 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $130.52 | 2021-2025 | Korlym |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Ramirez Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.